Sort by
Refine Your Search
-
Category
-
Program
-
Field
-
contract, working primarily from our site in Leuven. Part-time working conditions may be negotiable Full social security, including pension scheme and health care program We provide a supportive
-
Description We are seeking a motivated bioinformatics technician who wants to join the Guilliams and Scott labs with the VIB-Center for Inflammation Research. We have developed, and continue to
-
the successful delivery of genetically transformed plants for internal research and external stakeholders. In addition to transformation tasks, you will contribute to research and development aimed at improving
-
Alzheimer’s disease to develop and/or apply computational approaches to large scale genomic or transcriptomic datasets for identification of targets for early detection, prevention or treatment of Alzheimer’s
-
the development of genetic autoinflammatory diseases. Using techniques in cell biology, molecular biology and biophysics you will investigate how loss of function of the RNA editing enzyme ADAR1 causes the human
-
with therapeutic innovation and biotech development. The ICT team of the VIB-UGent Center for Inflammation Research (IRC) in Zwijnaarde is looking for a motivated and service-oriented IT Helpdesk
-
and business. VIB is committed to driving the growth of the life sciences cluster in Flanders. The VIB Technologies program is the institute's research infrastructure, offering access to cutting-edge
-
initiative investigating how human-specific features of brain development shape early behavior and neural circuit function in autism spectrum disorders (ASD). This position is a joint effort between the
-
Learning Expertise Unit at VIB.AI. Your role As an LLM Engineer, you will: Develop and deploy pilot projects in close collaboration with and tailored to VIB’s domain-specific centers, applying LLMs
-
. The candidate will work in a team of scientists dedicated to develop antisense oligonucleotides as disease-modifying therapeutics for neurodegenerative diseases. Our strategy is based on an innovative, all-in